{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:27:54Z","timestamp":1788834474301,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T00:00:00Z","timestamp":1459209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11523-016-0430-0","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T03:33:08Z","timestamp":1459222388000},"page":"605-617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment"],"prefix":"10.1007","volume":"11","author":[{"given":"Hiroki","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Omae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,29]]},"reference":[{"issue":"2","key":"430_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/sla.0000000000000628","volume":"261","author":"KW Reisinger","year":"2015","unstructured":"Reisinger KW, van Vugt JL, Tegels JJ, Snijders C, Hulsewe KW, Hoofwijk AG, et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg. 2015;261(2):345\u201352. doi: 10.1097\/sla.0000000000000628 .","journal-title":"Ann Surg"},{"issue":"31","key":"430_CR2","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1126\/sageke.2005.31.pe24","volume":"2005","author":"LP Fried","year":"2005","unstructured":"Fried LP, Hadley EC, Walston JD, Newman AB, Guralnik JM, Studenski S, et al. From bedside to bench: research agenda for frailty. Sci Aging Knowl Environ. 2005;2005(31):e24. doi: 10.1126\/sageke.2005.31.pe24 .","journal-title":"Sci Aging Knowl Environ"},{"issue":"8","key":"430_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s11605-012-1923-5","volume":"16","author":"P Peng","year":"2012","unstructured":"Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(8):1478\u201386. doi: 10.1007\/s11605-012-1923-5 .","journal-title":"J Gastrointest Surg"},{"issue":"18","key":"430_CR4","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1002\/cncr.28798","volume":"120","author":"SP Psutka","year":"2014","unstructured":"Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014;120(18):2910\u20138. doi: 10.1002\/cncr.28798 .","journal-title":"Cancer"},{"issue":"13","key":"430_CR5","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1245\/s10434-011-1976-9","volume":"18","author":"MS Sabel","year":"2011","unstructured":"Sabel MS, Lee J, Cai S, Englesbe MJ, Holcombe S, Wang S. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18(13):3579\u201385. doi: 10.1245\/s10434-011-1976-9 .","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"430_CR6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","volume":"17","author":"E Fabbro Del","year":"2012","unstructured":"Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240\u20135. doi: 10.1634\/theoncologist.2012-0169 .","journal-title":"Oncologist"},{"issue":"7","key":"430_CR7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s1470-2045(08)70153-0","volume":"9","author":"CM Prado","year":"2008","unstructured":"Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9(7):629\u201335. doi: 10.1016\/s1470-2045(08)70153-0 .","journal-title":"Lancet Oncol"},{"issue":"11","key":"430_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/bjs.9258","volume":"100","author":"N Harimoto","year":"2013","unstructured":"Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100(11):1523\u201330. doi: 10.1002\/bjs.9258 .","journal-title":"Br J Surg"},{"issue":"8","key":"430_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.urolonc.2015.01.011","volume":"33","author":"P Sharma","year":"2015","unstructured":"Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang J, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015;33(8):339. doi: 10.1016\/j.urolonc.2015.01.011 . e17-23.","journal-title":"Urol Oncol"},{"key":"430_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.08.071","author":"H Fukushima","year":"2015","unstructured":"Fukushima H, Nakanishi Y, Kataoka M, Tobisu KI, Koga F. Prognostic significance of sarcopenia in metastatic renal cell carcinoma patients. J Urol. 2015. doi: 10.1016\/j.juro.2015.08.071 .","journal-title":"J Urol"},{"issue":"8","key":"430_CR11","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","volume":"21","author":"S Antoun","year":"2010","unstructured":"Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21(8):1594\u20138. doi: 10.1093\/annonc\/mdp605 .","journal-title":"Ann Oncol"},{"issue":"5","key":"430_CR12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.2013.58","volume":"108","author":"O Huillard","year":"2013","unstructured":"Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034\u201341. doi: 10.1038\/bjc.2013.58 .","journal-title":"Br J Cancer"},{"issue":"5","key":"430_CR13","doi-asserted-by":"publisher","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","volume":"7","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7(5):e37563. doi: 10.1371\/journal.pone.0037563 .","journal-title":"PLoS One"},{"key":"430_CR14","doi-asserted-by":"publisher","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539\u201347. doi: 10.1200\/jco.2012.45.2722 .","DOI":"10.1200\/jco.2012.45.2722"},{"issue":"3","key":"430_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1017\/s0029665108007131","volume":"67","author":"DC McMillan","year":"2008","unstructured":"McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257\u201362. doi: 10.1017\/s0029665108007131 .","journal-title":"Proc Nutr Soc"},{"issue":"4","key":"430_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor MJ, Morrison DS, Talwar D, Balmer SM, O\u2019Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726\u201334. doi: 10.1038\/sj.bjc.6606087 .","journal-title":"Br J Cancer"},{"issue":"2","key":"430_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/bjc.2011.556","volume":"106","author":"GW Lamb","year":"2012","unstructured":"Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 2012;106(2):279\u201383. doi: 10.1038\/bjc.2011.556 .","journal-title":"Br J Cancer"},{"issue":"2","key":"430_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cncr.22400","volume":"109","author":"S Ramsey","year":"2007","unstructured":"Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007;109(2):205\u201312. doi: 10.1002\/cncr.22400 .","journal-title":"Cancer"},{"issue":"2","key":"430_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324. doi: 10.1056\/NEJMoa065044 .","journal-title":"N Engl J Med"},{"issue":"2","key":"430_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.bjc.6605167","volume":"101","author":"JS Thompson Coon","year":"2009","unstructured":"Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T, et al. Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br J Cancer. 2009;101(2):238\u201343. doi: 10.1038\/sj.bjc.6605167 .","journal-title":"Br J Cancer"},{"issue":"3","key":"430_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","volume":"58","author":"B Ljungberg","year":"2010","unstructured":"Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398\u2013406. doi: 10.1016\/j.eururo.2010.06.032 .","journal-title":"Eur Urol"},{"issue":"18","key":"430_CR22","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/cncr.28218","volume":"119","author":"S Antoun","year":"2013","unstructured":"Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377\u201384. doi: 10.1002\/cncr.28218 .","journal-title":"Cancer"},{"issue":"6","key":"430_CR23","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","volume":"97","author":"W Shen","year":"2004","unstructured":"Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97(6):2333\u20138. doi: 10.1152\/japplphysiol.00744.2004 .","journal-title":"J Appl Physiol (1985)"},{"issue":"3","key":"430_CR24","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jjco\/hyt232","volume":"44","author":"T Kondo","year":"2014","unstructured":"Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol. 2014;44(3):270\u20137. doi: 10.1093\/jjco\/hyt232 .","journal-title":"Jpn J Clin Oncol"},{"key":"430_CR25","unstructured":"Pfizer Japan. Sutent appropriate use guideline. Japan: Pfizer Japan; 2012."},{"key":"430_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.08.003","author":"H Li","year":"2015","unstructured":"Li H, Samawi H, Heng DY. The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol. 2015. doi: 10.1016\/j.urolonc.2015.08.003 .","journal-title":"Urol Oncol"},{"issue":"1","key":"430_CR27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1152\/jappl.2000.89.1.104","volume":"89","author":"BH Goodpaster","year":"2000","unstructured":"Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985). 2000;89(1):104\u201310.","journal-title":"J Appl Physiol (1985)"},{"issue":"2","key":"430_CR28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0014-5793(89)80805-1","volume":"250","author":"S Miki","year":"1989","unstructured":"Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989;250(2):607\u201310.","journal-title":"FEBS Lett"},{"issue":"2","key":"430_CR29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF01741856","volume":"35","author":"AS Koo","year":"1992","unstructured":"Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, deKernion JB, et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35(2):97\u2013105.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"430_CR30","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/0008-5472.can-13-1671","volume":"74","author":"T Cuadros","year":"2014","unstructured":"Cuadros T, Trilla E, Sarro E, Vila MR, Vilardell J, de Torres I, et al. HAVCR\/KIM-1 activates the IL-6\/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. Cancer Res. 2014;74(5):1416\u201328. doi: 10.1158\/0008-5472.can-13-1671 .","journal-title":"Cancer Res"},{"issue":"13","key":"430_CR31","first-page":"4653","volume":"9","author":"M Trikha","year":"2003","unstructured":"Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653\u201365.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"430_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153\u201366. doi: 10.1016\/j.cmet.2012.06.011 .","journal-title":"Cell Metab"},{"issue":"6","key":"430_CR33","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.amjmed.2005.10.049","volume":"119","author":"LA Schaap","year":"2006","unstructured":"Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119(6):526. doi: 10.1016\/j.amjmed.2005.10.049 . e9-17.","journal-title":"Am J Med"},{"issue":"7","key":"430_CR34","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/sj.bjc.6602152","volume":"91","author":"E Bromwich","year":"2004","unstructured":"Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer. 2004;91(7):1236\u20138. doi: 10.1038\/sj.bjc.6602152 .","journal-title":"Br J Cancer"},{"key":"430_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/coc.0000000000000061","author":"SJ Cushen","year":"2014","unstructured":"Cushen SJ, Power DG, Teo MY, Maceneaney P, Maher MM, McDermott R, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol. 2014. doi: 10.1097\/coc.0000000000000061 .","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"430_CR36","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P, Wood L, Garcia JA, Dreicer R, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084\u20139. doi: 10.1016\/j.ejca.2014.01.025 .","journal-title":"Eur J Cancer"},{"issue":"3","key":"430_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.juro.2013.08.090","volume":"191","author":"BJ Atkinson","year":"2014","unstructured":"Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611\u20138. doi: 10.1016\/j.juro.2013.08.090 .","journal-title":"J Urol"},{"issue":"8","key":"430_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. doi: 10.1056\/NEJMoa1303989 .","journal-title":"N Engl J Med"},{"key":"430_CR39","doi-asserted-by":"publisher","unstructured":"Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412\u20138. doi: 10.1200\/jco.2013.50.8267 .","DOI":"10.1200\/jco.2013.50.8267"},{"issue":"2","key":"430_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1517\/17425255.4.2.137","volume":"4","author":"M Kacevska","year":"2008","unstructured":"Kacevska M, Robertson GR, Clarke SJ, Liddle C. Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing. Expert Opin Drug Metab Toxicol. 2008;4(2):137\u201349. doi: 10.1517\/17425255.4.2.137 .","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-016-0430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-016-0430-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-016-0430-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-016-0430-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T01:46:54Z","timestamp":1567734414000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-016-0430-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,29]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s11523-016-0430-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,29]]}}}